Gemcitabine, Etoposide, Cisplatin, and Dexamethasone in Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Gemcitabine, Etoposide, Cisplatin, and Dexamethasone in Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma

Published:2009 Issue:1 Volume:24 Page:37
ISSN:1226-3303
Container-title:The Korean journal of internal medicine
language:en
Short-container-title:Korean J Intern Med

Author:

Kim Ki-Hyang¹,Joo Young-Don¹,Sohn Chang-Hak¹,Shin Ho-Jin²,Chung Joo-Seop²,Cho Goon-Jae²,Shin Sung-Hoon³,Kim Yang-Soo³,Lee Won-Sik¹

Affiliation:

1. Department of Hematology & Oncology, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea.

2. Department of Hematology & Oncology, Pusan National University Hospital, Busan, Korea.

3. Department of Hematology & Oncology, Kosin University Hospital, Busan, Korea.

Publisher

Korean Association of Internal Medicine

Link

http://synapse.koreamed.org/pdf/10.3904/kjim.2009.24.1.37

Reference22 articles.

1. EPIC: an effective low toxicity regimen for relapsing lymphoma

2. High-dose therapy and autologous bone marrow transplantation for adult patients with lymphoblastic lymphoma: results of the European Group for Bone Marrow Transplantation.

3. Promising activity of gemcitabine in refractory high-grade non-Hodgkin's lymphoma

4. Gemcitabine as a Single Agent in the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

5. Treatment of refractory T-cell malignancies using gemcitabine

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Analysis of the efficacy and safety of a combined gemcitabine, oxaliplatin and pegaspargase regimen for NK/T-cell lymphoma;Oncotarget;2016-04-07

2. Biweekly dose-dense gemcitabine-oxaliplatin and dexamethasone for relapsed/refractory aggressive non-Hodgkin lymphoma: A multicenter, single-arm, phase II trial;Asia-Pacific Journal of Clinical Oncology;2016-03-09

3. Clinical Efficacy and Safety in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Systematic Literature Review;Clinical Lymphoma Myeloma and Leukemia;2014-10

4. Comparison of gemcitabine, oxaliplatin and L-asparaginase and etoposide, vincristine, doxorubicin, cyclophosphamide and prednisone as first-line chemotherapy in patients with stage IE to IIE extranodal natural killer/T-cell lymphoma: a multicenter retrospective study;Leukemia & Lymphoma;2014-08-20

5. DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center;Annals of Hematology;2013-03-27

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3